Source link : https://newshealth.biz/health-news/fda-slams-pfizer-for-talzenna-biomarker-free-push/
Pfizer was taken to task at a recent meeting of the US Food and Drug Administration (FDA)’s Oncologic Drugs Advisory Committee (ODAC) for attempting to expand the use of its prostate cancer drug talazoparib (Talzenna) to men lacking a key biomarker without providing sufficient evidence of benefit. “It’s tantamount to somebody shooting an arrow on […]
The post FDA Slams Pfizer for Talzenna Biomarker-Free Push first appeared on News Health.
—-
Author : News Health
Publish date : 2025-05-29 11:33:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8